Cholera is an enteric disease caused by Vibrio cholerae. Toxin-coregulated pilus (TCP), a type 4 pilus expressed by V. cholerae, is a cholera virulence factor that is required for host colonization. The TCP polymer is composed of subunits of TcpA pilin. Antibodies directed against TcpA are protective in animal models of cholera. While natural or recombinant forms of TcpA are difficult to purify to homogeneity, it is anticipated that synthesized TcpA peptides might serve as immunogens in a subunit vaccine. We wanted to assess the potential for effects of the immune response ( 
Cholera is an acute diarrheal disease caused by the gramnegative bacterium Vibrio cholerae. The major secreted or surface-expressed virulence factors of V. cholerae are cholera toxin and toxin-coregulated pilus (TCP) (7; reviewed in reference 9). TCP is a type 4 pilus composed of a homopolymer of 20.5-kDa TcpA pilin subunits that mediate V. cholerae colonization (8, 11, 20, 22) . The TCP is allelic, i.e., there are two predominant biotype-specific derivatives of TcpA (classical and El Tor), which differ by 18.1% at the protein level in the region defined by amino acids 145 to 199 (15) . TcpA and peptides derived from it are immunogenic and induce protective antibodies (Abs) when not delivered in the context of a natural infection or vaccination with intact bacteria (7, (16) (17) (18) (19) . Anti-TCP Abs when mixed with virulent V. cholerae (500 times the 50% lethal dose [LD 50 ]) and fed to infant mice provide almost complete immunity to cholera (16, 17) . The regions of classical TcpA that neutralizing Abs are directed against have been partially defined. Results of several experimental approaches have indicated that domains within the C-terminal region of TcpA (amino acids 145 to 199) delineated by a single disulfide bond can induce the protective Ab response seen in animals (16, 17) . Peptides Cl-4, Cl-5, and Cl-6 induce immune responses in mice that can protect 50 to 89% of infant mice against a 100LD 50 challenge in the infant mouse cholera model (17) . Recent results (24) have further demonstrated that TcpA-derived peptides and new experimental polymer adjuvants induce Ab responses in female mice that protect their pups from V. cholerae infection. The previous studies were focused on the classical biotype of TCP. TCP of El Tor biotypes has not been analyzed for protective epitopes of peptides 4, 5, and 6. Therefore, it is of interest to compare the immunogenicities of peptides 4, 5, and 6 of the two TCP biotypes.
The effects of the immune response (Ir) gene were first described in 1965 by McDeveitt and Sella (12) . They showed that a branched polymer composed of a backbone of L-lysine with side chains of DL-alanine conjugated randomly with tyrosine-glutamate when emulsified in Freund's complete adjuvant (FCA) was able to induce a robust Ab response in C57BL/6 mice (H-2 b ) and only a low Ab response in CBA mice (H-2 k ). This and similar phenomena were described as effects of the Ir gene. Interestingly, the (C57BL/6 ϫ CBA)F 1 mice made intermediate responses. These results, along with results from an F 1 ϫ C57BL/6 cross that showed a predominantly high response, suggested that a single gene was controlling the serologic response. Long-term studies using congenic mice clearly implicated the H-2 locus between K and Ss as containing the genes that controlled this phenomenon. Subsequent studies have shown that the major histocompatibility complex class II (MHC-II) molecules are critical for induction of Ab responses and that it is the associated genes in the H-2 locus that mediate the effects of the Ir gene. In the past 35 years, scientists have defined the role of class II in the induction of CD4 ϩ T-cell help for Ab formation. We know that binding peptide antigens (a fragment of the B-cell-internalized antigen) in the class II binding cleft is critical for B-cell presentation of the complex to CD4
ϩ T helper cells. The allelic variations in class II molecules among the H-2 types dictate the ability to bind peptides and thus the capacity to activate antigen-specific CD4 ϩ T cells (2, 5, 14, 23) . There is a compelling data set that indicates that the peptide and H-2 sequences must be optimized for effective presentation to induce T-cell help.
If subunit vaccines based on protein sequences are to be useful, they must be able to induce responses in a large per-centage of the target population. Classical peptides 4, 5, and 6 are 24 to 26 amino acids in length. Thus, they are long enough to contain both B-cell epitopes (binds surface immunoglobulin to select a B cell) and T-cell epitopes (presented by class II to provide T-cell help). This has been demonstrated for peptides 4 and 6 in CD-1 mice, which are outbred mice of the H-2 q haplotypes (24) . The issue at hand is to determine if the serologic and protective responses to peptides 4, 5, and 6 are indicative of universal T-cell epitopes for class II molecules or whether the effects of the Ir gene will be evident from limited amino acid sequences. In addition, the allelic differences between Cl and El Tor TCP biotypes could complicate a simple assignment of reactivity based on H-2 type.
MATERIALS AND METHODS
Animals. Three-to 5-week-old female congenic mice were purchased from Jackson Laboratory (Bar Harbor, Maine). At 8 weeks, 4 to 6 mice per haplotype group were immunized as described below. 4 ) were all prepared in-house using chemicals purchased from Fisher Scientific (Pittsburgh, Pa.) and Sigma. Methoxyflurane (Metofane) was manufactured by Schering-Plough Animal Health Corp. (Union, N.J.). Heparinized microhematocrit capillary tubes were purchased from Fisher Scientific. Seal-Rite 1.5-ml Natural microcentrifuge tubes and 0.5-ml self-standing microcentrifuge tubes with O-ring caps were purchased from USA Scientific, Inc. Perfektum 5-ml glass needle-lock tip syringes and Popper 20-gauge microemulsifying needles were purchased from Fisher Scientific. 3,3Ј,5,5Ј-Tetramethylbenzidine (TMB) peroxidase substrate was purchased from Kirkegaard & Perry Laboratories (Gaithersburg, Md.). All horseradish peroxidaseconjugated secondary Abs were purchased from Southern Biotechnology Associates (Birmingham, Ala.). One-milliliter Luer-Lok latex-free syringes and 22-gauge PrecisionGlide needles used to deliver the immunogens were manufactured by Becton Dickinson and Co. and were purchased from the local stockroom. Falcon PRO-BIND 96-well U-bottom assay plates used to dilute antisera for enzyme-linked immunosorbent assay (ELISA) were purchased from Fisher Scientific.
Peptides. TcpA fragment peptides 4, 5, and 6, derived from sequences of either classical or El Tor biotypes of V. cholerae, were commercially prepared by Macromolecular Resources (Colorado State University, Fort Collins, Colo.). The peptides used in single letter amino acid code are as follows: ET-4, ADLG DFETSVADAATGAGVIKSIA; ET-5, AATGAGVIKSIAPGSANLNLTNITH; ET-6, LNLTNITHVEKLCTGTAPFTVAFGNS; Cl-4, ADLGDFENSAAAAET GVGVIKSIA; Cl-5, AETGVGVIKSIAPASKNLDLTNITH; Cl-6, LDLTNIT HVEKLCKGTAPFGVAFGNS. The relative positions of these peptides are shown in Fig. 1 . The lyophilized peptides were resuspended in 5.0% dimethyl sulfoxide-water-0.25ϫ PBS to a final concentration of 0.5 mg/ml and stored at Ϫ80°C in 1.0-ml aliquots until used.
Immunization and serum collection. Peptide antigen emulsions were prepared by diluting peptides in 1ϫ PBS and then mixing with adjuvant in a 1:1 ratio. Mice were administered peptides (25 g/mouse) via intraperitoneal injection (200 l/mouse) with FCA for the primary inoculation (day 0) and with FIA for the secondary and tertiary inoculations (days 14 and 28). Preimmune sera were collected 1 to 2 weeks before the primary immunization. The primary-response sera were collected at day ϩ14, and the secondary-and tertiary-response sera were collected at days ϩ28 and ϩ42, respectively.
Blood collection was conducted under light methoxyflurane anesthesia via the orbital venous sinus and plexus or via the tail vein when necessary. The blood was incubated for 30 min at 37°C immediately following collection and then kept at 4°C overnight. Samples were centrifuged at 4°C for 10 min at 10,000 ϫ g, and 20-to 25-l aliquots of sera were stored at Ϫ20°C until used.
Serology. Costar 96-well, high-binding, flat-bottom microtiter plates (Corning Incorporated Life Sciences, Acton, Mass.) were coated with 0.5 g of peptides in 100 l of 0.1 M Na 2 HPO 4 , pH 9.0, overnight at 4°C. Plates were washed four times using a Molecular Devices (Sunnyvale, Calif.) Skan Washer 400 microplate washer with 250 l of 1ϫ PBS-0.05% Tween 20. Nonspecific binding was blocked using 200 l of 1ϫ PBS-0.05% Tween 20-1% bovine serum albumin for 1 h at room temperature. Plates were washed four more times, and 50 l of serially twofold-diluted antiserum was added to each well and incubated at room temperature for 2 h and then overnight at 4°C. The initial dilutions were 1:500 for preimmune and primary sera, 1:1,000 for secondary sera, and 1:2,000 for tertiary sera, except for Cl-5 tertiary sera, for which a dilution of 1:2,500 was used for the analysis. Plates were washed six times, and 50 l of horseradish peroxidase-labeled goat anti-mouse IgG1 (␥1 chain-specific) or IgG 2a (␥2a chainspecific) detector antibodies (diluted 1:4,000) was added to each well and incubated at room temperature for 2 h protected from light. Plates were washed eight times and were then developed with 100 l of 3,3Ј,5,5Ј-tetramethylbenzidine peroxidase substrate for 15 to 30 min at room temperature. The reaction was stopped with an equal volume of 0.18 M H 2 SO 4 . Optical densities were read using a Dynex Technologies MRX microplate reader (Thermo Labsystems, Helsinki, Finland) using Dynex Revelation, version 3.04, software at 450 nm with 630 nm as the reference wavelength.
Data analysis and statistics. All calculations and statistical analyses were performed with Microsoft Excel, version 9.0, and GraphPad Prism, version 3.0. The end point titer was defined as the reciprocal of the dilution for the last positive well for each sample after subtracting the background. Background values were defined as twice the mean optical density for all blank wells on a single microtiter plate. Wells containing the lowest dilution for prebleed samples were chosen to be blank background wells. One blank well was selected for each mouse on an individual plate.
Immune responses to the peptides by each haplotype were scored using the following criteria. A ϩ was awarded for each set of sera (primary, secondary, or tertiary) if all the mice responded to the immunization. If only two sets of sera responded e.g., secondary and tertiary, the group was scored ϩϩ. If all the mice associated with all three serum sets responded, the score was ϩϩϩ. A further refinement in the scoring was based on the totality of the response. Responses by more than one mouse, but not the entire group, for a particular sera set were scored ϩ/Ϫ. If no mice or only one mouse in the group responded, the group was scored Ϫ. If more than one mouse, but not all the mice, showed a positive response in the primary and secondary sera, yet the tertiary sera were all positive, the group was scored ϩ/Ϫ/ϩ/Ϫ/ϩ. To generate the number for the comparison of the immune index, groups were assigned scores based on the response pattern: ϩ, 5 points; ϩ/Ϫ, 2.5 points; Ϫ, 0 points. The values for the responses of the mice with various haplotypes to classical and El Tor TcpA peptides 4, 5, or 6 were tabulated (see Table 2 ). In addition, the immunogenicities of the peptides across the haplotypes were determined and related to IgG subclass responses.
RESULTS
We selected four congenic strains of mice that represent the three most studied class II H-2 regions: The IgG2a responses to Cl-4 for H-2 a , H-2 d , and H-2 k mice were also positive but of significantly less magnitude than the IgG1 responses (Fig. 3B) (Fig. 2) . The H-2 a mouse response to ET-4 for IgG2a was very robust compared to the anti-IgG2a response to Cl-4. The rank orders of response of the various haplotypes of mice to Cl-4 and ET-4 were as fol-
Cl-5 and ET-5. H-2 a , H-2 d
, and H-2 k mice responded with robust IgG1 titers to Cl-5 (Fig. 4A ). H-2 b mice were again nonresponders to Cl-5. The IgG2a responses to Cl-5 of all the mice were low or absent (Fig. 4B ). There was variability in H-2 d and H-2 k mice in the secondary and tertiary responses (IgG2a) to Cl-5, with not all of them responding. This was clearly different from the IgG1 responses of mice in these two haplotypes in which the overwhelming majority of the mice responded earlier and with higher titers of anti-Cl-5 IgG1. Clearly, for all mice that responded to immunization with Cl-5, the IgG1 response was induced earlier and to a higher degree than that for IgG2a.
As with immunization of mice with ET-4, immunization with ET-5 revealed effects of the Ir gene. Specifically, H-2 b mice did not respond to Cl-5 ( Fig. 4A and B 
FIG. 3. Comparison of ELISA titers of classical and El Tor antipeptide 4 IgG1 (A) or IgG2a (B).
End point titers are shown as the reciprocal of the dilution for the last positive well for each serum analyzed. Cl-4 or ET-4 was bound to the plates in 0.1 M Na 2 HPO 4 , pH 9.0, at a concentration of 5 g/ml. Preimmune and primary sera were diluted to 1:500, secondary sera were diluted to 1:1,000, and tertiary sera were diluted to 1:2,000. Dotted lines, baseline serum dilution. haplotype mice were nonresponders to ET-6 but responded to Cl-6. This is in contrast to H-2 a mice responding to ET-4 and ET-5. Immunization with either Cl-6 or ET-6 revealed a difference in the abilities of I-A k /I-E k mice to respond to a given peptide. H-2 a mice did not respond to ET-6 while H-2 k mice did. This was based on differences that map to the class I region of H-2.
The response to IgG2a of the various congenic mice to Cl-6 was similar to the IgG1 response (Fig. 5B) .0, at a concentration of 5 g/ml. Preimmune and primary sera were diluted to 1:500, secondary sera were diluted to 1:1,000, and tertiary sera were diluted to 1:2,000, except for classical sera, which were diluted 1:2,500. Dotted lines, baseline serum dilution. Symbols above the lines are considered positive. Means are indicated by solid lines.
FIG. 5. Comparison of ELISA titers of classical and El
Tor antipeptide 6 IgG1 (A) or IgG2a (B). End point titers are shown as the reciprocal of the dilution for the last positive well for each serum analyzed. Cl-6 or ET-6 were bound to the plates in 0.1 M Na 2 HPO 4 , pH 9.0, at a concentration of 5 g/ml. Preimmune and primary sera were diluted to 1:500, secondary sera were diluted to 1:1,000, and tertiary sera were diluted to 1:2,000. Dotted lines, baseline serum dilution. Symbols above the lines are considered positive. be the same. Thus, the likely explanation for the lack of, or low, serologic response by a particular haplotype of mouse would be an effect of the Ir gene because of the loss of T-cell epitopes.
To explore further evidence for B-cell epitopes in peptides 4, 5, and 6 of the two biotypes, we performed cross-binding assays (Table 1) . We assessed, for example, whether Cl-4-specific antisera could bind the ET-4 peptide, which would suggest common B-cell epitopes. The lengths of common sequences between the classical and El Tor peptides are extensive enough, 7 to 12 amino acids, to provide common linear B-cell epitopes. Based on high-titer responses (homologous system) in their tertiary serum, two mice from each of the haplotype groups were chosen for various peptide combinations. In this comparison, we divided the end point titer obtained in the homologous system by the end point titer obtained in the heterologous system analysis. If the B-cell epitopes for given classical and ET peptides are the same or very similar, the titers for the cross-binding assay should be identical (classical/El Tor and El Tor/classical quotients of 1 to 0.04). If there are no common B-cell epitopes between biotype-equivalent peptides, the titer ratio (classical/El Tor or El Tor/classical) will be 0. If there are one or more cross-reactive B-cell epitopes but the binding of the heterologous peptide-induced sera is lower than that of the homologous system, the titers will be above background but lower than those for the homologous system (classical/El Tor or El Tor/classical quotient ratio of 0.008 to 0.002).
This analysis indicates that peptide 4 is the most crossreactive, producing an average cross-reactive score of 0.55 and a mode of 1. Peptide 5 was the least cross-reactive peptide, with an average of 0.24 for a cross-reactive score and a mode of 0. Peptide 6 was cross-reactive but not as cross-reactive as peptide 4. The average cross-reactivity score for peptide 6 was 0.52 with a dual mode of 0 or 0.008.
If one examines the peptide-haplotype combinations ( Table  1 ) that were suggestive of the effects of the Ir gene, it is apparent that biotype differences can affect both T-and B-cell epitopes. The Cl-4 H-2 a group reveals identity in the crossreactivity analysis, suggesting that the lack of response is not due to lack of a common B-cell epitope. Since the class II restriction element is the same in these haplotypes, another explanation (effects of the class I Ir gene) is required to explain the lack of a serologic response.
The cross-binding responses to peptide 5 are suggestive of limited or no common B-cell epitopes. The biotype sequences of peptide 5 have more-limited areas for B-cell epitopes because of the significant nature of the amino acid differences between the biotypes of TcpA. The cross-binding score of Cl-5 antisera from H-2 d mice is unusual in peptide 5 comparisons, as it indicates near identity (score of 0.2 or 0.04) between Cl-5 and ET-5 for H-2 d mouse sera. In particular, the changes Cl-E158 to ET-A158, Cl-K172 to ET-A172, and Cl-D176 to ET-N176 suggest that it would be difficult to maintain B-cell reactivity of peptide 5, thus focusing common B-cell epitopes on sequences in the middle of the peptide. The data in Table  1 suggest that there are not sufficient common sequences in Cl-5 or ET-5 to accommodate Ab binding. Alternatively, the B-cell epitopes that are immunogenic in the different biotypes of TcpA 5 are different.
The differences in the abilities of H-2 a and H-2 k mice to respond to Cl-6 and ET-6 is likely based on a change in the B-cell epitope due to the amino acid differences between the biotypes. The cross-binding score for these haplotype-peptide combinations is in the middle range, suggesting positive but not optimal binding. The dominant B-cell epitope in response to Cl-6 or ET-6 immunization (H-2 a versus H-2 k ) should not change the class II binding capacity of the epitopes but does alter binding of Abs, suggesting that the B-cell epitope(s) is near the site of amino acid differences between the biotypes which, because of their nature (Cl-D175 to ET-N175, Cl-G189 to ET-T189, and Cl-V195 to ET-T195) would likely be disruptive for Ab binding.
Immune indices of classical and El Tor peptides 4, 5, and 6. The anti-peptide 4, 5, and 6 responses of mice immunized with classical or El Tor peptides were scored as described in Materials and Methods and are shown in Table 2 . The compari- a Tertiary sera for two individual mice for selected biotype-specific antiserum peptides were analyzed for reactivity by ELISA. Not all the sera for all the combinations presented in Fig. 2 to 4 were analyzed in this table. End-point titers were calculated for each serum and ratios of titers were calculated for classical antisera against classical peptide or El Tor peptide (Cl/ET) or for El Tor antisera against El Tor peptide or classical peptide (ET/Cl). Ratios of cross-reactivity were calculated by dividing the heterologous titer by the homologous titer. Ratios of 1 to 0.04 were considered indicative of highly cross-reactive sera. Ratios that produced a quotient of 0 were considered descriptive of non-cross-reactive sera. Ratios of Ͼ0.04 to 0.002 were considered indicative of low cross-reactivity. Average ratios were calculated for each peptide analyzed and modes were determined for the data set presented in Table 2 sons in Table 2 a and H-2 k mice are surprising and are not correlated with class II differences but with other H-2 region gene differences (Fig. 2) .
If the immunogenicities of biotype-equivalent classical and El Tor peptides across the haplotypes are examined, it is apparent that peptides 6 (97.5) and 4 (92.5), regardless of the biotype, are the most immunogenic if both IgG1 and IgG2a responses are considered. The response to peptide 5 (72.5) is lower and more variable for the individual biotypes of peptides and for the IgG subclasses. Clearly, peptide 5 sequences are less immunogenic in the haplotypes of mice tested, which may correlate with the limited class II isotype that is expressed (I-A b only).
DISCUSSION
Cholera remains a disease for which a universal, highly effective vaccine is lacking (3, 4) . The development of a cholera vaccine must take into account the target population and the current biotype and serotype of the endemic or pandemic organism. The success of the Bordetella pertussis subunit vaccine, which is based in part on the immunogenicity of three colonization factors and their capacity to evoke protective serologic responses, has prompted us to evaluate a similar approach for V. cholerae vaccination (11) . The only well-defined colonization factor in cholera infection is TCP although it has been suggested that others have a role (18) (19) (20) (21) . A complicating factor in the use of TCP as an immunogen is the difficulty in isolating endotoxin-free TcpA from cultured bacteria.
A potential TcpA vaccine that could circumvent the LPS contamination could be based on TCP-derived peptides. TcpA peptides have been generated based on the classical TcpA amino acid sequences that span the C terminus of the TcpA subunit (18) . This region of TcpA is defined by a predicted ␤ hairpin turn with a disulfide bond that contains amino acids required for assembly of the pilus and also for interaction with either host cells or cells in the aggregated colony of bacteria (10) . Corresponding peptides from regions in El Tor TcpA have not been investigated for their protective effect.
The synthesis of peptides corresponding to regions of TcpA overcomes the problem of purification, but it introduces a new problem: the potential effect of the Ir gene associated with a limited peptide sequence available for class II binding. Effects of the Ir gene are classically defined as lower immunogenicity of a protein that has been linked to the lack of peptide binding to class II molecules and thus to no or poor activation of T-cell help for Ab production. Initial studies suggested that classical peptides 4, 5, and 6 were immunogenic, but these studies did not investigate enough potential class II alleles to determine if Fig. 3 to 5, in which the anti-peptide 4, 5, and 6 responses for individual mice in the primary, secondary, and tertiary antisera were assessed. The reactivities of the group for a given serum set were scored as follows: Ϫ, 0 (no response); ϩ/Ϫ, 2.5 (partial response for more than one mouse but not all); ϩ, 5 (total response). The values in this table were used to generate the rank order of the reactivity for a given peptide shown in Results.
the effects of the Ir gene would be problematic. In this study, we clearly demonstrate that the three most common H-2 haplotypes of mice manifest significant effects of the Ir gene with respect to these peptides, as evidenced by different levels of serologic responses in selected TcpA biotype and haplotype combinations. These effects are seen in both the classical and El Tor biotypes. Furthermore, there is a non-class II but H-2-linked effect on the immunogenicities of classical and El Tor peptides. This is seen in the response of H-2 a and H-2 k mice to peptides 4 or 6. In the peptide 4 system, Cl-4 is immunogenic in mice of both haplotypes, whereas only the H-2 a mice respond to (25) . The B cells then become a target for cytotoxic T-lymphocyte (CTL) responses that kill the B cells and thus reduce or prevent antibody responses to the immunizing antigen. Thus, we hypothesize that, for ET-4 and ET-6, the differences in class I resulted in presented peptides that make B cells in H-2 k and H-2 a mice, respectively, targets for CTL-based elimination. Clearly, there are a number of uncharacterized genes, with the percent contributions for these genes in congenic mice being unknown because of the unmapped recombination point. If one eliminates non-immune-related genes as the explanation for the differences in response to ET-4 and CL-6, then class I and Qa-2 differences are both theoretical possibilities. Qa-2 antigens are nonclassical MHC-I molecules with the potential to bind peptides. The Qa-2 antigen is the product of the Ped (preimplantation embryo development) gene and is a glycosylphosphatidylinositol-linked cell surface protein encoded in the Q region of the mouse major histocompatibility region (13 a and H-2 k mice. Qa-2 effects could account for the lack of peptide 4 responses, and class I differences could account for the lack of a peptide 6 response.
While we have identified effects of the Ir gene for classical and El Tor TcpA peptides, it is apparent that other genes can affect the serologic response as well. The reason that H-2 a mice are such good responders is not apparent and is not related to the Ig locus as they share that with H-2 k mice. Other non-H-2 genes linked to H-2 may contribute to the differences in serologic responses. Regardless of the explanation for the differences, the effect of the Ir gene associated with the differences in the H-2 regions suggests that vaccine peptides based on classical and El Tor TcpA peptide 4, 5, or 6 may not be universally efficacious in the human population. This may be an overstatement, as the target human population is outbred at the HLA locus. The codominant expression of human class II molecules DR, DQ, and DP might allow more possible targets for classical peptide-and El Tor peptide-based binding. Thus, with more class II alleles present, it may be easier to generate a class II peptide complex to induce T-cell help for antibody production. It is, however, also true that certain proteins contain immunodominant epitopes for induction of responses, and thus, while TcpA peptide 4, 5, or 6 binding may occur at a high frequency, the peptide sequences may not be particularly immunogenic with respect to their ability to be highly expressed and thus able to activate naive T cells. There are two solutions to these issues. The most direct, and one that can take advantage of T-cell memory in the mucosal T-cell pool, would be to link classical and El Tor peptide 4, 5, or 6 to a universal protein carrier for its contribution of T-cell epitopes. A recent development by Alexander et al. could also be used by taking advantage of pan-DR epitopes that could be linked to the TcpA peptide, thus yielding a host (human)-based vaccine design based on known class II binding properties (1) . Alternatively, a mixture of TcpA peptides that would more effectively cover the possible sequence solutions to MHC-II binding may be used. These solutions would mitigate the effect of the class II Ir gene but not the possible effect of class I or Qa-2 (perhaps not evident in humans, as no Qa-2 gene has been identified). The solution for the class I-based problem of the classical and El Tor peptide sequences is to clearly identify the TcpA B-cell epitopes within peptides 4, 5, and 6 that are immunogenic and protective and then use minimal B-cell epitopes as haptens associated with a universal carrier.
Clearly, the development of cholera subunit vaccines for humans will need to take into account the route of immunization that induces the most protective isotype. Whether this is secretory IgA or IgG is debatable, but the resolution of this issue may dictate the route and method of immunization with TcpA peptides. We were able to induce IgG as well as IgA (data not shown) via intraperitoneal immunization. While this form of immunization is not practical in humans, other routes such as oral or intranasal routes have been shown to be responsive to immunogens by generating IgG as well as serum IgA.
